This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Patients who present with hemophilia A require treatment to replace low levels of Factor VIII (FVIII). Intervention can either be on demand or prophylactically. The goal of therapy is to prevent joint bleeds that lead to permanent damage. The progression of therapy in hemophilia A has provided patients with options resulting in a greatly improved quality of life. The newest development of gene therapy, to replace FVIII, may be the answer to cure this disease. This review provides a historical account of the treatment for hemophilia A as well as current available treatment options.
- Received August 6, 2019.
- Accepted August 7, 2019.
- Published by American Society for Clinical Laboratory Science